3. Initial evaluation of the safety of autologous immunotherapy in patients with lung cancer
Main Article Content
Abstract
This descriptive study aimed to assess the safety of autologous immune cell infusions (natural killer (NK) cells or gamma delta T ((ƔδT) cells) in 10 patients with non-small cell lung cancer at Hanoi Medical University Hospital. Safety was evaluated at the following timepoints: during treatment, at the end of treatment, and at 3- and 6-month after treatment. Adverse events were classified using the CTCAE 5.0 guidelines (2017). Among five patients who received NK cell infusion, common adverse events including fatigue (6.7%), loss of appetite (6.7%), insomnia (6.7%), diarrhea (6.7%), and constipation (6.7%); vomiting (3.3%) was the least common adverse event. For the five patients who received ƔδT cell infusion, fever was the most common adverse event (6.7%), followed by anorexia, muscle pain, and joint pain (3.3%). One patient had a mild reduction in leukocytes, granulocytes, and platelets 6 months after treatment. All clinical and paraclinical unwanted side effects were moderate and transient, categorized as grade 1 by CTCAE 5.0, and required no treatment. This investigation provides preliminary evidence supporting the safety of autologous NK/ƔδT cell immunotherapy in lung cancer treatment.
Article Details
Keywords
Autologous immune, natural killer cells, gamma delta T cells, adverse events
References
2. Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020; 124: 109821. doi:10.1016/j.biopha.2020.109821.
3. Liem NT, Van Phong N, Kien NT, et al. Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam. Int J Mol Sci. 2019; 20(13): 3166. doi:10.3390/ijms20133166.
4. Xiao Z, Wang CQ, Feng JH, et al. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non–small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials. Cytotherapy. 2019; 21(2): 125-147. doi:10.1016/j.jcyt.2018.10.011.
5. Ding X, Cao H, Chen X, et al. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. Journal of Translational Medicine. 2015; 13(1): 158. doi:10.1186/s12967-015-0514-0.
6. Nakajima J, Murakawa T, Fukami T, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg. 2010; 37(5): 1191-1197. doi:10.1016/j.ejcts.2009.11.051.
7. Kakimi K, Matsushita H, Murakawa T, Nakajima J. γδ T cell therapy for the treatment of non-small cell lung cancer. Transl Lung Cancer Res. 2014; 3(1): 23-33. doi:10.3978/j.issn.2218-6751.2013.11.01.
8. Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023; 23(2): 90-105. doi:10.1038/s41577-022-00732-1.
9. Zou C, Zhao P, Xiao Z, Han X, Fu F, Fu L. γδT cells in cancer immunotherapy. Oncotarget. 2017; 8(5): 8900-8909. doi:10.18632/oncotarget.13051.
10. Common Terminology Criteria for Adverse Events (CTCAE). Published online 2017.
11. Jia L, Chen N, Chen X, et al. Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum- containing chemotherapy. Front Immunol. 2022; 13:1074906. doi:10.3389/fimmu.2022.1074906.
12. Kim EJ, Cho YH, Kim DH, et al. A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer. Cancer Res Treat. 2022; 54(4): 1005-1016. doi:10.4143/crt.2021.986.